HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Petros Includes Nitrate Patients In OTC ED Drug Self-Selection Studies

Executive Summary

Firms also notes in its announcement that FDA typically requires actual use trials for switch NDAs in addition to label comprehension studies, which it has conducted, and self-selection studies.

You may also be interested in...



Poland’s Adamed Secures Tadalafil Rx-To-OTC Switch In World First

Poland becomes the first country in the world to allow erectile dysfunction treatment tadalafil to be bought without a prescription thanks to a successful Rx-to-OTC switch application from local player Adamed Pharma.

Distributing Health, Beauty Products To Retailers, Hims & Hers Seeds Field For OTC ED Drug Sales

With ED ingredients frequently mentioned as OTC switch candidates in US, Hims & Hers Health is another latest direct-to-consumer marketer establishing network of retailers to offer potential OTC ED drug as it makes its consumer health and personal care products available in stores.

Label Comprehension Results Point Petros Toward OTC Self-Selection Study For Stendra ED Drug

Petros considers switch NDA for Stendra (avanafil), approved for Rx sales in US since 2012 on an NDA by Metuchen. Early indicators showed positive outcomes in a 453-subject label comprehension study for the oral PDE5 inhibitor.

Related Content

Topics

UsernamePublicRestriction

Register

RS152130

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel